drugset / Trial / NCT02970669

Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.

NCT02970669

Phase 4 Completed 140 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindOther

Summary

The purpose of this study was to investigate the effects of initiation of sacubitril/valsartan vs enalapril treatment on objective measures of both waking activity and sleep in subjects with heart failure with reduced ejection fraction.

Timeline

Start
2016-12-16
Primary completion
2018-03-19
Completion
2018-03-19

Drugs

EvaluationDrugModalityDoseRoute
Comparator Enalapril Other / unclassified 2.5 mg Oral
Comparator Enalapril Other / unclassified 10 mg Oral
Subject sacubitril/valsartan Unknown Oral

Indications